Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calderasib alone or with cetuximab in KRAS G12C-mutant advanced solid tumors
NCT07209111Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Apr 2032
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of calderasib in solid tumor, sponsored by Merck & Co.. Started Dec 2025; status: recruiting.
02
Drugs
calderasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07209111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209111.